STAAR Surgical (STAA) in our Pivotal Point Check: China Rebound in Implantable Contact Lenses Shatters Expectations with $90 Million Quarterly Revenue!
Reading Time: 2 minutes
Revenue surge: Preliminary figures for Q1 2026 come in at over $90 million, vastly exceeding expectations of $68.8 million. China rebound: The normalization of inventory levels with the key trading partner results in a doubling of last year's revenue. Margin focus: An improved cost structure leads experts to anticipate a significant increase in adjusted EBITDA. STAAR Surgical, a global leader in the development and manufacturing of implantable contact lenses, surprised Wall Street on April 9, 2026. The stock soared by 20% on extremely...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
